URSODEOXYCHOLIC ACID MARKET ANALYSIS

Ursodeoxycholic Acid Market, By Dosage Form (Solid Dosage Form and Liquid Dosage Form), By Mode of Extraction (Synthetic and Biological), By Application (Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On August 14, 2024, Gilead Sciences, Inc. announced that the U.S. FDA had granted accelerated approval for Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) in adults. It can be used with ursodeoxycholic acid (UDCA) for those with an inadequate response, or as monotherapy for those unable to tolerate UDCA. Livdelzi is not recommended for patients with decompensated cirrhosis.
In June 2024, Ipsen announced that the U.S. FDA had granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for treating primary biliary cholangitis (PBC) in adults. It can be used in combination with ursodeoxycholic acid (UDCA) for those with an inadequate response to UDCA, or as monotherapy for those unable to tolerate UDCA. Iqirvo is now available for eligible patients in the U.S.
In April 2022, PharmaZell, Farmabios, and Novasep merged to form Axplora, significantly bolstering the company’s presence in the active pharmaceutical ingredients sector. This merger is expected to propel the market's exponential expansion.
In August 2020, ICE s.p.a. acquired New Zealand Pharmaceuticals (NZP), a company specializing in the production of active pharmaceutical ingredients (APIs) and intermediates derived from bile. This acquisition enhanced ICE's geographic reach, expanded its product knowledge, and strengthened its bile acid portfolio, contributing to the company's global market expansion.